The Safety Pharmacology Society is pleased to invite you to a webinar presentation on Thursday, December 5, 2019 at 11:00 EST, 16:00 UTC (GMT) / 17:00 CET.
Title: How can safety pharmacology benefit from human heart disease modelling and simulations?
Presenter: Elisa Passini, PhD, University of Oxford
Abstract: Human in silico trials constitute an emerging technology to predict drug safety and efficacy. Candidate compounds can be tested on human-based computer models for an early identification of potential adverse events, as well as selection of the ones most likely to succeed. The high variability in drug responses makes risk predictions for the whole population very challenging. In addition, adverse events are more likely to occur in diseased patients, having some underlying condition or taking concomitant medications.
This webinar illustrates the role and maturity of multiscale computer modelling and simulations of the human heart in safety pharmacology. Representative examples on the use of these models for human in silico drug trials are presented, from single cell to the whole organ level, both in control and diseased conditions. Drug-induced changes to cardiac electrophysiology and contractility are investigated to identify the sub-populations of patients at higher risk of developing cardiac adverse events, and the ones which would benefit more from a specific treatment.
The integration of human in silico drug trials with the other techniques currently used for safety pharmacology will lead to safer and better medicine, contributing to provide digital evidence for safety and efficacy decision making in the early stages of drug development.
Moderator: Eric I. Rossman, PhD, GlaxoSmithKline
FREE for all SPS Members
$50 fee per webinar
We look forward to your participation.
Safety Pharmacology Society Headquarters